Skip to main content
Erschienen in: Virchows Archiv 5/2009

01.05.2009 | Original Article

Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites

verfasst von: Shigeki Sekine, Yukihiro Nakanishi, Reiko Ogawa, Satoko Kouda, Yae Kanai

Erschienen in: Virchows Archiv | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

Mucosal melanomas have genetic alterations distinct from those in cutaneous melanomas. For example, NRAS- and BRAF-activating mutations occur frequently in cutaneous melanomas, but not in mucosal melanomas. We examined 16 esophageal melanomas for genetic alterations in NRAS, BRAF, and KIT to determine whether they exhibit genetic features common to melanomas arising from other mucosal sites. A sequencing analysis identified NRAS mutations in six cases; notably, four of these mutations were located in exon 1, an uncommon mutation site in cutaneous and other mucosal melanomas. BRAF and KIT mutations were found in one case each. Immunohistochemistry showed KIT expression in four cases, including the tumor with a KIT mutation and two other intramucosal tumors. The low frequency of BRAF mutations and the presence of a KIT mutation-positive case are findings similar to those of mucosal melanomas of other sites, but the prevalence of NRAS mutations was even higher than that of cutaneous melanomas. The present study implies that esophageal melanomas have genetic alterations unique from those observed in other mucosal melanomas.
Literatur
1.
Zurück zum Zitat van't Veer LJ, Burgering BM, Versteeg R et al (1989) N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 9:3114–3116 van't Veer LJ, Burgering BM, Versteeg R et al (1989) N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 9:3114–3116
2.
Zurück zum Zitat Jiveskog S, Ragnarsson-Olding B, Platz A et al (1998) N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 111:757–761PubMedCrossRef Jiveskog S, Ragnarsson-Olding B, Platz A et al (1998) N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol 111:757–761PubMedCrossRef
3.
Zurück zum Zitat Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMedCrossRef
4.
Zurück zum Zitat Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147PubMedCrossRef Curtin JA, Fridlyand J, Kageshita T et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135–2147PubMedCrossRef
5.
Zurück zum Zitat Curtin JA, Busam K, Pinkel D et al (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340–4346PubMedCrossRef Curtin JA, Busam K, Pinkel D et al (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340–4346PubMedCrossRef
6.
Zurück zum Zitat Rivera RS, Nagatsuka H, Gunduz M et al (2008) C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 452:27–32PubMedCrossRef Rivera RS, Nagatsuka H, Gunduz M et al (2008) C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 452:27–32PubMedCrossRef
7.
Zurück zum Zitat Antonescu CR, Busam KJ, Francone TD et al (2007) L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121:257–264PubMedCrossRef Antonescu CR, Busam KJ, Francone TD et al (2007) L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 121:257–264PubMedCrossRef
8.
Zurück zum Zitat Kato H, Watanabe H, Tachimori Y et al (1991) Primary malignant melanoma of the esophagus: report of four cases. Jpn J Clin Oncol 21:306–313PubMed Kato H, Watanabe H, Tachimori Y et al (1991) Primary malignant melanoma of the esophagus: report of four cases. Jpn J Clin Oncol 21:306–313PubMed
9.
Zurück zum Zitat Li B, Lei W, Shao K et al (2007) Characteristics and prognosis of primary malignant melanoma of the esophagus. Melanoma Res 17:239–242PubMedCrossRef Li B, Lei W, Shao K et al (2007) Characteristics and prognosis of primary malignant melanoma of the esophagus. Melanoma Res 17:239–242PubMedCrossRef
10.
Zurück zum Zitat Lohmann CM, Hwu WJ, Iversen K et al (2003) Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens. Melanoma Res 13:595–601PubMedCrossRef Lohmann CM, Hwu WJ, Iversen K et al (2003) Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens. Melanoma Res 13:595–601PubMedCrossRef
11.
Zurück zum Zitat Turnbull AD, Rosen P, Goodner JT et al (1973) Primary malignant tumors of the esophagus other than typical epidermoid carcinoma. Ann Thorac Surg 15:463–473PubMedCrossRef Turnbull AD, Rosen P, Goodner JT et al (1973) Primary malignant tumors of the esophagus other than typical epidermoid carcinoma. Ann Thorac Surg 15:463–473PubMedCrossRef
12.
Zurück zum Zitat Scotto J, Fraumeni JF Jr, Lee JA (1976) Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst 56:489–491PubMed Scotto J, Fraumeni JF Jr, Lee JA (1976) Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst 56:489–491PubMed
13.
Zurück zum Zitat Tateishi R, Taniguchi H, Wada A et al (1974) Argyrophil cells and melanocytes in esophageal mucosa. Arch Pathol 98:87–89PubMed Tateishi R, Taniguchi H, Wada A et al (1974) Argyrophil cells and melanocytes in esophageal mucosa. Arch Pathol 98:87–89PubMed
14.
Zurück zum Zitat Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28:578–588PubMedCrossRef Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28:578–588PubMedCrossRef
15.
Zurück zum Zitat Cohen Y, Rosenbaum E, Begum S et al (2004) Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 10:3444–3447PubMedCrossRef Cohen Y, Rosenbaum E, Begum S et al (2004) Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 10:3444–3447PubMedCrossRef
16.
Zurück zum Zitat Edwards RH, Ward MR, Wu H et al (2004) Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 41:270–272PubMedCrossRef Edwards RH, Ward MR, Wu H et al (2004) Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet 41:270–272PubMedCrossRef
17.
Zurück zum Zitat Wong CW, Fan YS, Chan TL et al (2005) BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 58:640–644PubMedCrossRef Wong CW, Fan YS, Chan TL et al (2005) BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 58:640–644PubMedCrossRef
18.
Zurück zum Zitat Lasota J, Jasinski M, Sarlomo-Rikala M et al (1999) Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154:53–60PubMed Lasota J, Jasinski M, Sarlomo-Rikala M et al (1999) Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154:53–60PubMed
19.
Zurück zum Zitat Hodi FS, Friedlander P, Corless CL et al (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046–2051PubMedCrossRef Hodi FS, Friedlander P, Corless CL et al (2008) Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 26:2046–2051PubMedCrossRef
20.
Zurück zum Zitat Lutzky J, Bauer J, Bastian BC (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21:492–493PubMedCrossRef Lutzky J, Bauer J, Bastian BC (2008) Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 21:492–493PubMedCrossRef
21.
Zurück zum Zitat Montone KT, van Belle P, Elenitsas R et al (1997) Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 10:939–944PubMed Montone KT, van Belle P, Elenitsas R et al (1997) Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Mod Pathol 10:939–944PubMed
22.
Zurück zum Zitat Janku F, Novotny J, Julis I et al (2005) KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 15:251–256PubMedCrossRef Janku F, Novotny J, Julis I et al (2005) KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. Melanoma Res 15:251–256PubMedCrossRef
Metadaten
Titel
Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites
verfasst von
Shigeki Sekine
Yukihiro Nakanishi
Reiko Ogawa
Satoko Kouda
Yae Kanai
Publikationsdatum
01.05.2009
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 5/2009
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-009-0762-6

Weitere Artikel der Ausgabe 5/2009

Virchows Archiv 5/2009 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …